메뉴 건너뛰기




Volumn 19, Issue 4, 2012, Pages 1051-1055

The combination of surgery and imatinib in GIST: A reality for localized tumors at high risk, an open issue for metastatic ones

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

EID: 84862490305     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2191-4     Document Type: Editorial
Times cited : (29)

References (20)
  • 1
    • 84861759106 scopus 로고    scopus 로고
    • Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132
    • doi:10.1245/s10434-011-2190-5
    • Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol. 2011. doi:10.1245/s10434-011-2190-5.
    • (2011) Ann Surg Oncol
    • Wang, D.1    Zhang, Q.2    Blanke, C.D.3    Demetri, G.D.4    Heinrich, M.C.5    Watson, J.C.6
  • 3
    • 77954319411 scopus 로고    scopus 로고
    • Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • ESMO/CONTICANET/EUROBONET Consensus Panel of Experts
    • Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v98-102.
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • Casali, P.G.1    Blay, J.Y.2
  • 4
    • 80053465153 scopus 로고    scopus 로고
    • Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)
    • Joensuu H, Eriksson M, Hartmann J, Sundby Hall K, Schútte J, Reichardt A, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol. 2011;15(Suppl, May 20):LBA1.
    • (2011) J Clin Oncol , vol.15 , Issue.SUPPL. MAY 20
    • Joensuu, H.1    Eriksson, M.2    Hartmann, J.3    Sundby Hall, K.4    Schútte, J.5    Reichardt, A.6
  • 5
    • 62849096370 scopus 로고    scopus 로고
    • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial
    • Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-104.
    • (2009) Lancet , vol.373 , pp. 1097-1104
    • Dematteo, R.P.1    Ballman, K.V.2    Antonescu, C.R.3    Maki, R.G.4    Pisters, P.W.5    Demetri, G.D.6
  • 6
    • 78649673624 scopus 로고    scopus 로고
    • Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001
    • Corless CL, Ballman BV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28(Suppl, May 20):10006.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. MAY 20 , pp. 10006
    • Corless, C.L.1    Ballman, B.V.2    Antonescu, C.3    Blanke, C.D.4    Blackstein, M.E.5    Demetri, G.D.6
  • 7
    • 77949898532 scopus 로고    scopus 로고
    • Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients
    • Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST)
    • Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247-53.
    • (2010) J Clin Oncol , vol.28 , pp. 1247-1253
  • 9
    • 84867300058 scopus 로고    scopus 로고
    • Frequencies of KIT and PDGFRAmutations in theMolecGIST prospective population-based study differ from those of advanced GISTs
    • doi:10.1007/s12032-011-0074-y
    • Emile JF, Brahimi S,Coindre JM, Bringuier PP,MongesG, Samb P, et al. Frequencies of KIT and PDGFRAmutations in theMolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011. doi:10.1007/s12032-011-0074-y.
    • (2011) Med Oncol
    • Emile, J.F.1    Brahimi, S.2    Coindre, J.M.3    Bringuier, P.P.4    MongesG5    Samb, P.6
  • 11
    • 67349212626 scopus 로고    scopus 로고
    • Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
    • Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739-45.
    • (2009) Eur J Surg Oncol , vol.35 , pp. 739-745
    • Fiore, M.1    Palassini, E.2    Fumagalli, E.3    Pilotti, S.4    Tamborini, E.5    Stacchiotti, S.6
  • 12
    • 33846635001 scopus 로고    scopus 로고
    • Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations
    • DOI 10.1245/s10434-006-9228-0
    • Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007;14:526-32. (Pubitemid 46175297)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.2 , pp. 526-532
    • Haller, F.1    Detken, S.2    Schulten, H.-J.3    Happel, N.4    Gunawan, B.5    Kuhlgatz, J.6    Fuzesi, L.7
  • 14
    • 33644667084 scopus 로고    scopus 로고
    • Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
    • Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006;93:304-11.
    • (2006) J Surg Oncol , vol.93 , pp. 304-311
    • Rutkowski, P.1    Nowecki, Z.2    Nyckowski, P.3    Dziewirski, W.4    Grzesiakowska, U.5    Nasierowska-Guttmejer, A.6
  • 16
    • 34247610583 scopus 로고    scopus 로고
    • Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    • DOI 10.1097/01.sla.0000236630.93587.59, PII 0000065820070300000003
    • DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347-52. (Pubitemid 46673128)
    • (2007) Annals of Surgery , vol.245 , Issue.3 , pp. 347-352
    • DeMatteo, R.P.1    Maki, R.G.2    Singer, S.3    Gonen, M.4    Brennan, M.F.5    Antonescu, C.R.6
  • 17
    • 34247615184 scopus 로고    scopus 로고
    • Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST
    • DOI 10.1097/01.sla.0000242710.36384.1b, PII 0000065820070300000002
    • Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341-6. (Pubitemid 46673127)
    • (2007) Annals of Surgery , vol.245 , Issue.3 , pp. 341-346
    • Gronchi, A.1    Fiore, M.2    Miselli, F.3    Lagonigro, M.S.4    Coco, P.5    Messina, A.6    Pilotti, S.7    Casali, P.G.8
  • 18
    • 47149107052 scopus 로고    scopus 로고
    • Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)
    • Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008;98:27-33.
    • (2008) J Surg Oncol , vol.98 , pp. 27-33
    • Sym, S.J.1    Ryu, M.H.2    Lee, J.L.3    Chang, H.M.4    Kim, T.W.5    Kim, H.C.6
  • 20
    • 77957341199 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial
    • Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11:942-9.
    • (2010) Lancet Oncol , vol.11 , pp. 942-949
    • Le Cesne, A.1    Ray-Coquard, I.2    Bui, B.N.3    Adenis, A.4    Rios, M.5    Bertucci, F.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.